

[10] **Patent/Publication Number:** WO2003091213A1

[43] **Publication Date:** Nov. 06, 2003

[54] **NOVEL AMIDE DERIVATIVES OR SALTS THEREOF**

[72, 75] **Inventor(s):**

ONDA; Kenichi, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka, Tsukuba-shi
Ibaraki 305-8585 JP JP JP

SUZUKI; Takayuki, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka, Tsukuba-shi
Ibaraki 305-8585 JP JP JP

SHIRAKI; Ryota, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka, Tsukuba-shi
Ibaraki 305-8585 JP JP JP

YONETOKU; Yasuhiro, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,
Tsukuba-shi Ibaraki 305-8585 JP JP JP

OGIYAMA; Takashi, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,
Tsukuba-shi Ibaraki 305-8585 JP JP JP

MARUYAMA; Tatsuya, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,
Tsukuba-shi Ibaraki 305-8585 JP JP JP

MOMOSE; Kazuhiro, c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,
Tsukuba-shi Ibaraki 305-8585 JP JP JP

[71] **Assignee/Applicant:**

YAMANOUCHI PHARMACEUTICAL CO.; LTD., 3-11, Nihonbashi-Honcho 2-chome,
Chuo-ku Tokyo 103-8411 JP JP JP

[30] **Priority:**

JP Apr. 25, 2002 2002-123926

[21] **Application Number:** JP0305198 JP

[22] **Application Date:** Apr. 23, 2003

[51] **Int. Cl.⁷:** A61K031404

A61K031407 A61K031427 A61K0314439 A61K031497 A61K031506 C07D20942

[56] **References Cited:**

U.S. PATENT DOCUMENTS

9639384 /PCIT WO [0]

FOREIGN PATENT DOCUMENTS

9639385 /PCIT WO [0]

1088824 /REFS EP [0]

Attorney, Agent, or Firm - NAGAI, Shozo

[57] **ABSTRACT**

It is intended to provide compounds of the following general formula (I) which are glycogen

phosphorylase inhibitors and useful as remedies and preventives for insulin-dependent diabetes (type 1 diabetes), insulin- independent diabetes (type 2 diabetes), insulin resistant disease and obesity. Namely, glycogen phosphorylase inhibitors characterized by having an indole ring, etc. bonded to a ring A (an aryl ring or an aromatic heterocycle) via an amide bond and the ring A having a hydroxyethylene moiety as a substituent. It is still preferable that the glycogen phosphorylase inhibitors are characterized in that the above- described ring A has a dihydroxyethylene moiety as a substituent. (I) wherein each substituent is as defined in claim 1.

DETAILS

NotAvailable

CLAIMS (ENGLISH)

NotAvailable

CLAIMS (FRENCH)

NotAvailable

CLAIMS (GERMAN)

NotAvailable

NotAvailable

* * * * *